新冠病毒疫苗市場：依疫苗類型、通路和地區分類

Coronavirus Vaccine Market, By Vaccine Type, By Distribution Channel, By Geography

出版日期: 2026年03月12日 | 出版商:

Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計，新冠病毒疫苗市場在2026年的價值為544.9億美元，預計到2033年將達到909.9億美元。預計從2026年到2033年，其複合年成長率將達到7.6%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	544.9億美元
歷史數據時期：	2020-2024	預測期：	2026-2033
2026年至2033年預測期間的複合年成長率：	7.60%	2033年市場規模預測：	909.9億美元

新冠肺炎疫情是近期爆發的感染疾病疫情，最快於2019年12月31日在中國武漢報告。新冠肺炎是由一種名為SARS-CoV-2的冠狀病毒引起的病毒感染疾病，主要影響呼吸系統。新冠肺炎傳染性極強，可透過與感染者直接接觸或間接接觸周圍環境中的物體表面傳播。此外，新冠肺炎病例數量正在迅速增加，使其成為全球大流行病。例如，根據世界衛生組織（世衛組織）發布的《新冠肺炎疫情每週流行病學報告》，截至2022年5月30日，全球報告感染疾病超過1.69億例，死亡人數超過350萬人。

市場動態

市場參與者正在推進臨床試驗，以開發更有效的COVID-19疫苗，預計在預測期內將推動市場成長。例如，去年12月，Zydus Cadila宣布其ZyCoV-D疫苗已通過I期和II期臨床試驗。該公司研發的COVID-19預防性質體DNA疫苗在I期和II期臨床試驗中均被證實安全、耐受性良好且免疫抗原性。

市場相關人員正集中精力推進該產品的上市和核准，預計將鞏固其在全球市場的地位。例如，2021年12月，阿斯特捷利康的新冠疫苗在英國核准緊急供應，首劑疫苗已交付，預計於2022年初開始接種。英國藥品和保健產品監管局（MHRA）核准了阿斯特捷利康新冠疫苗（原名AZD1222）的緊急供應，用於18歲及以上人群的主動免疫接種。此核准建議接種兩劑，間隔4至12週。

市場相關人員正積極尋求非內內部成長策略，例如合作、合資、併購等，以加強新冠疫苗的分銷。預計這將加速新冠疫苗市場的成長。例如，2021年8月14日，美國衛生與公眾服務部（HHS）和國防部（DoD）與Moderna公司簽署協議，由該公司在2022年前生產並交付1億劑在美國生產的新冠疫苗。

本研究的關鍵特徵

本報告對全球新冠疫苗市場進行了詳細分析，顯示了 2026 年至 2033 年預測期內的市場規模和複合年成長率（%）。
本報告揭示了各細分市場的潛在商機，並說明了該市場極具吸引力的投資提案矩陣。此外，報告還深入分析了市場促進因素、限制因素、機會、區域前景以及主要參與者採取的競爭策略。
本報告根據以下參數對全球冠狀病毒疫苗市場的主要參與者進行了分析：公司概況、財務表現、產品系列、企業發展區域、主要發展和未來計劃。
透過利用本報告中提出的見解，企業行銷負責人和經營團隊將能夠就未來的市場擴張和行銷策略做出明智的決策。
全球新冠疫苗市場報告的目標受群眾外包括行業內的各類相關人員，例如投資者、產品開發商和製造商、經銷商、醫療機構、研究機構、新參與企業和金融分析師。
相關人員可以透過利用全球新冠疫苗市場分析中使用的各種策略矩陣進行決策，從而獲得極大的益處。

公司簡介
- Pfizer-BioNtech
- AstraZeneca
- Bharat BIoTech
- Johnson & Johnson Services, Inc
- Moderna, Inc.
- Sinovac BIoTech Ltd.
- Serum Institute of India Pvt. Ltd.
- Sanofi SA
- Novavax, Inc.
- Symvivo
- CanSinoBIO
- CureVac AG
- Zydus Cadila
- Arcturus Therapeutics Holdings Inc.
- Entos Pharmaceuticals

第5章

參考
調查方法

簡介目錄

Product Code: CMI4320

Coronavirus Vaccine Market is estimated to be valued at USD 54.49 Bn in 2026 and is expected to reach USD 90.99 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.6% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 54.49 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	7.60%	2033 Value Projection:	USD 90.99 Bn

The coronavirus (COVID-19) pandemic is the most recent outbreak, which was first reported on December 31, 2019, in Wuhan, China. COVID-19 is a viral infection caused by a coronavirus called SARS-CoV-2, which affects the respiratory tract. The COVID-19 is highly contagious and can be transmitted through direct contact with the infected person or indirect contact with surfaces in the immediate environment. Moreover, the number of people getting infected by COVID-19 has dynamically increased, making it a global pandemic. For instance, according to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 169 million cases and 3.5 million deaths due to coronavirus disease (COVID-19) were reported up till May 30, 2022 across the globe.

Market Dynamics

Market players are conducting clinical trials for developing more efficient vaccines against COVID-19, which could contribute to the growth of the market over the forecast period. For instance, in December, Zydus Cadila announced that ZyCoV-D vaccine cleared phase 1 and phase 2 trials. The company's plasmid DNA vaccine to prevent COVID-19, was found to be safe, well tolerated, and immunogenic in phase 1 and 2.

Market players are focusing on product launch and approvals, which is expected to strengthen their position in the global market. For instance, in December 2021, AstraZeneca's COVID-19 vaccine was approved for emergency supply in the U.K., with the first doses being released, so that vaccinations may begin by early 2022. The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) provided authorization for emergency supply of COVID-19 vaccine AstraZeneca, formerly AZD1222, for the active immunization of individuals 18 years or older. The authorization recommends two doses administered in an interval of between four and 12 weeks.

Market players are involved in inorganic growth strategies such as partnerships, collaborations, mergers, and acquisitions, in order to enhance distribution of COVID 19 vaccines. This is expected to drive the growth of the coronavirus vaccine market. For instance, on August 14, 2021, the U.S. Department of Health and Human Services (HHS) and Department of Defense (DoD) entered into an agreement with Moderna, Inc. to manufacture and deliver 100 million doses of COVID-19 vaccines produced by the company in the U.S. by 2022.

Key features of the study

This report provides in-depth analysis of the global coronavirus vaccine market, and provides market size (US$ Bn) and compound annual growth rate (CAGR) (%) for the forecast period 2026 - 2033.
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, regional outlook, and competitive strategies adopted by the leading players.
It profiles leading players in the global coronavirus vaccine market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, key developments, and future plans.
Key companies covered as a part of this study include Sinovac Biotech Ltd., Bharat Biotech International Limited, BioNTech SE, CanSinoBIO, CureVac AG, Zydus Cadila, AstraZeneca Plc, Arcturus Therapeutics Holdings Inc., Entos Pharmaceuticals, Symvivo, Novavax, Inc., Moderna, Inc., Johnson & Johnson, Sanofi S.A., Pfizer, Inc., and Serum Institute of India Pvt. Ltd.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansions and marketing tactics
The global coronavirus vaccine market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global coronavirus vaccine market

Market Segmentation

Global Coronavirus Vaccine Market, By Vaccine Type (Revenue, USD Bn, 2021 - 2033)
Inactivated Virus
Protein Subunit
Non-replicating Viral Vector
Repurposed Vaccines
RNA Vaccine
DNA Vaccine
By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
Government Channels
Hospitals
Clinics
Others
Global Coronavirus Vaccine Market, By Region (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Company Profiles
Pfizer-BioNtech
AstraZeneca
Bharat Biotech.
Johnson & Johnson Services, Inc
Moderna, Inc.
Sinovac Biotech Ltd.
Serum Institute of India Pvt. Ltd.
Sanofi S.A.
Novavax, Inc.
Symvivo
CanSinoBIO
CureVac AG
Zydus Cadila
Arcturus Therapeutics Holdings Inc.
Entos Pharmaceuticals
GlaxoSmithKline
EyeGene Inc.
Arcturus Therapeutics
Takara Bio

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Vaccine Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Competitive Landscape

Company Profiles
- Pfizer-BioNtech
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- AstraZeneca
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Bharat Biotech
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Johnson & Johnson Services, Inc
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Moderna, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Sinovac Biotech Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Serum Institute of India Pvt. Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Sanofi S.A.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Novavax, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Symvivo
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- CanSinoBIO
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- CureVac AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Zydus Cadila
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Arcturus Therapeutics Holdings Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Entos Pharmaceuticals
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies